Company Profile

Virtech Bio Inc
Profile last edited on: 3/14/23      CAGE: 7KSG4      UEI: DX5PHGT3N4U9

Business Identifier: Novel, proprietary hemoglobin-based oxygen carrier (HBOC) solution: OxyBridge. Both for in vivo & ex vivo applications.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

27 Strathmore Road
Natick, MA 01760
   (508) 627-0485
Location: Single
Congr. District: 05
County: Essex

Public Profile

An early-stage biotech company based in Natick, MAandhaving alimited SBIR presence, VirTech Bio has developed a novel, proprietary hemoglobin-based oxygen carrier (HBOC) solution - OxyBridge - for use both in vivo and ex vivo applications: a proprietary HBOC solution for in vivo applications like severe blood loss and such ex vivo applications as supporting organs prior to transplant. Though not recently SBIR involved. the firm's team of scientists, engineers and industry veterans are committed to delivering a universal HBOC solution to fulfill significant unmet medical needs and save lives when minutes matter that deserves acknowldgement with their efforts worthy of note. Specifically, the firm is organzied around the critical task of transforming current organ transplant science, technologies and techniques to provide more reliable, effective and life saving solutions for humanity. With hemorrhage being the leading cause of trauma-related death in both civilian and military populations, as a firm Virtech Bio Inc is focused on reshaping the modern blood replacement system. With the firm's lead product called OxyBridge™ - Supercharged oxygen delivery, Human-derived, hemoglobin-based - principals of the firm have developed a room-temperature stable, ready-to-use oxygen-carrying plasma expander to restore circulatory system parameters in pre-hospital settings. The firm is developing innovative therapies for organ and tissue preservation, ex vivo organ management and biomarker discovery using a technology platform combining machine perfusion (MP) with a new hemoglobin-based oxygen carrier (HBOC). With current transplant protocols sometimes leading to damaged organs and suboptimal outcomes, VirTech has developed a novel approach for oxygen delivery while managing organs and tissue outside the body improving organ quality and extends viability

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 1 SOCOM $148,088
Project Title: Enhanced Canine Performance, Protection and Survivability
2016 1 NIH $238,970
Project Title: Human-Derived Hemoglobin Based Oxygen Carrier for Utilization in Organ and Tissue Preservation

Key People / Management

  Matias Vidal -- Co-Founder, Chairmanof Board, former Chief Executive Officer and Director

  Phil Farabaugh -- Vice President, Operations

  Col (Ret) Dallas Hack -- CEO and Director, Medical Affairs

  William Richard Light -- Chief Scientific Officer

  Joseph Tucker

  Kim Vandegriff -- Vice President, Research & Development

  Andrew Wright -- Vice President, Marketing